CYMABAY THERAPEUTICS INC (CBAY)

Company Profile

CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. The company is headquartered in Newark California, California and currently employs 60 full-time employees. The company went IPO on 2014-01-16. The firm is focused on developing therapies for patients with liver and other chronic diseases. The firm's lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation, and fibrosis. The company is focused on developing seladelpar for the treatment of primary biliary cholangitis (PBC), an autoimmune disease that causes progressive destruction of the bile ducts in the liver resulting in impaired bile flow (cholestasis) and inflammation. Its other product candidate, MBX-2982, targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion.

Company Info

CYMABAY THERAPEUTICS INC

Suite 130, 7999 Gateway Blvd

Newark California CALIFORNIA 94560

P: 15102938800

CEO: Sujal Shah

Employees: 60

Website: https://www.cymabay.com/